NCT00290381View on ClinicalTrials.gov

The Effects of OC000459 on Nasal Mediators

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

Not specified

Primary Completion Date

February 1, 2005

Conditions

Allergic Rhinitis

Interventions

PROCEDURE

Oxagen OC000459

Trial Locations (1)

SW3 6HP

National Heart & Lung Institute Clinical Studies Unit, London

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Oxagen Ltd

INDUSTRY

lead

Trevor Hansel

OTHER